Table 2.
Summary of preliminary results of CAR T/CAR NK cell therapy for AML.
| Product | Target Antigen | Phase | Disease State | Clinical Outcome | NCT ID |
|---|---|---|---|---|---|
| CAR T (2nd gen) | Lewis-Y Ag | I | R/R | Transient blast decrease 1/4pts | NCT01716364 |
| CD33 | I | R/R | Marked blast decrease 1pt | NCT02799680 | |
| CAR T | NKG2D | I | R/R | CRh+CRi 3/7pts | NCT02203825 |
| Compound CAR T | CLL-1 and CD33 | I | R/R | MRD neg 1 pt | NCT03795779 |
| CAR-NK | CD33 | I | R/R | Decrease in MRD 1/3pts | NCT02944162 |
R/R: relapsed/refractory; MRD: minimal residual disease; CRh: hematologic complete remission; CRi: complete remission without complete hematologic recovery.